Who is sponsoring NCT00375596?

NCT00375596 is sponsored by Bausch & Lomb Incorporated.

What drugs are being tested in NCT00375596?

Interventions in NCT00375596: Ketotifen/vasoconstrictor.

What condition does NCT00375596 study?

NCT00375596 studies Allergic Conjunctivitis.

Is NCT00375596 still recruiting?

NCT00375596 is currently withdrawn. Last updated 20 February 2015.

Last reviewed 2015-02-20 · How we verify

NCT00375596

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis

Withdrawn Phase 2 Last updated 20 February 2015

What this trial tests

Phase 2 trial testing Ketotifen/vasoconstrictor in Allergic Conjunctivitis. Withdrawn.

Quick facts

Lead sponsor	Bausch & Lomb Incorporated
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Design	parallel

Drugs / interventions tested

Ketotifen/vasoconstrictor — full drug profile →

Conditions studied

Allergic Conjunctivitis — all drugs for Allergic Conjunctivitis →

Sponsor

Bausch & Lomb Incorporated — full company profile →

Who can join

6 and older, any sex, with Allergic Conjunctivitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate the safety and efficacy of a new allergy medication

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Allergic Conjunctivitis

Currently open trials in the same condition.

NCT07309432 — Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy · Phase 3 · recruiting
NCT06686472 — Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis · Phase 2 · recruiting

Other Bausch & Lomb Incorporated trials

Trials by the same sponsor.

NCT07054606 — A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear · Phase 4 · completed
NCT06803654 — A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Rel · Phase 3 · completed
NCT06594185 — A Study to Evaluate Real World Outcomes of the enVista® Aspire (EA) and Aspire Toric (ETA) Intraocular Lens in Subjects · NA · completed
NCT06479148 — Clinical Evaluation of the Performance of the enVista® Aspire™ (EA) Lens · NA · terminated
NCT06333028 — A Study to Evaluate the enVista® Aspire (EA) Intraocular Lens in Subjects Undergoing Cataract Extraction · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00375596 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bausch & Lomb Incorporated
Last refreshed: 20 February 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00375596.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing